Stock Spotlight

Stock Spotlight: Nanosonics Ltd (ASX:NAN)

Stock Spotlight: Nanosonics Ltd (ASX:NAN)

Key stats

$1.18B
Market cap
$3.8850
Share price
30.10%
1 year return
77.80
P/E ratio
N/A
Dividend yield
1.75
Beta
0.0500
EPS
PEG ratio
7.53%
Short interest
Healthcare
Industry

Source: Yahoo Finance. Data as of 05/08/25.

About Nanosonics

Nanosonics Limited operates as an infection prevention company globally. The company manufactures and distributes the trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. Its product portfolio includes trophon2 that provides protection across various level disinfection HLD cycle; AuditPro nanosonics, an infection control workflow compliance management; Trophon EPR, a patented sonicated mist technology that provides high level disinfection of both endocavitary and surface ultrasound probes; and CORIS, an instrument reprocessing product platform. The company was incorporated in 2000 and is headquartered in Macquarie Park, Australia.

Price Performance

Growth Potential

  • Requirement for ultrasound disinfection. Ultrasound transducers must be disinfected between patients to prevent cross-infection. Trophon EPR is a significant improvement above traditional methods (soak, spray, wipe or other manual reprocessing/disinfection method). For instance, traditional soaking takes ~25 minutes versus Trophon which takes ~7-8 minutes to disinfect ultrasound probes.
  • Potential addressable installed base of ~120,000 Trophon EPR units globally (~40,000 in the US, Europe and Rest of World each).
  • New guidelines and regulation drive pathways to reinforce requirements for high level disinfection. For instance, new guidelines in Australia and New Zealand setting Trophon as the standard in high level disinfection.
  • Continued growth in North America to be driven by its direct sales team with adoption remaining strong and Trophon becoming the standard of care.
  • CORIS launch in FY26 could potentially exceed market expectations
  • Large and credible distribution partner is retained in GE Healthcare with demand for safety inventory.
  • Managed Equipment Service business model (MES) in the UK overcoming capital budget constraints by clients.
  • Progress with geographic expansion.
  • Strong balance sheet to support growth strategy

Key Risks

  • Competitive pressures as potential entrants enter the market.
  • Non-receptive markets where NAN’s product is considered overkill compared to traditional disinfection methods such as using sterilized wipes.
  • CORIS launch in FY26 disappoints relative to expectations.
  • Key customer risk as one customer is NAN’s largest customer.
  • Product faults or incidents where recalls are required.
  • Adverse foreign currency movements in AUD/USD.
  • Poor execution of R&D with no progress.
  • Nature of business makes it prone to easily reaching a natural penetration rate, where growth becomes subdued.

Frequently asked questions

This article is general information only and does not take into account your objectives, financial situation or needs. It is not a recommendation to buy or sell any security. Past performance is not a reliable indicator of future performance. Consider seeking financial, legal and taxation advice before investing.

Newsletter

Get our insights in your inbox

Join the Sharewise newsletter for new market insights and stock spotlights, plus invites to company webinars and Stocks and Sips evenings.

More articles

All news →

Want more than one article's worth?

Sharewise clients get ongoing research, Advisor access and execution across ASX, US and global markets.

Explore our services →